Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer.
Cancer Res., Feb;68(3):731-9 (2008)
Preliminary report of the effect of high-dose adjuvant intensity modulated radiation therapy on the sural nerve graft for cavernosal nerve sacrifice after radical prostatectomy.
Am. J. Clin. Oncol., Aug;30(4):395-400 (2007)
Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis.
Hum. Pathol., Nov;38(11):1688-95 (2007)
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Clin. Cancer Res., Aug;12(16):4872-5 (2006)
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer.
Technol. Cancer Res. Treat., Feb;5(1):23-36 (2006)
CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer.
Cancer Biol. Ther., Jan;5(1):78-83 (2006)
Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer.
Urology., Jan;65(1):131-5 (2005)
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
J. Urol., Sep;172(3):900-4 (2004)
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Int. J. Radiat. Oncol. Biol. Phys., Jun;59(2):562-71 (2004)
Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Urology., May;63(5):905-10; discussion 910-1 (2004)
Predictors of prostate cancer after initial negative systematic 12 core biopsy.
J. Urol., May;171(5):1850-4 (2004)
Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy.
J. Urol., Mar;171(3):1089-92 (2004)
Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy.
J. Urol., Jan;171(1):204-9 (2004)